JP6188934B2 - デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 - Google Patents
デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 Download PDFInfo
- Publication number
- JP6188934B2 JP6188934B2 JP2016520593A JP2016520593A JP6188934B2 JP 6188934 B2 JP6188934 B2 JP 6188934B2 JP 2016520593 A JP2016520593 A JP 2016520593A JP 2016520593 A JP2016520593 A JP 2016520593A JP 6188934 B2 JP6188934 B2 JP 6188934B2
- Authority
- JP
- Japan
- Prior art keywords
- dexmedetomidine
- delivery device
- transdermal delivery
- subject
- transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887870P | 2013-10-07 | 2013-10-07 | |
| US61/887,870 | 2013-10-07 | ||
| PCT/US2014/059057 WO2015054062A2 (en) | 2013-10-07 | 2014-10-03 | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017146472A Division JP6522062B2 (ja) | 2013-10-07 | 2017-07-28 | デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532645A JP2016532645A (ja) | 2016-10-20 |
| JP2016532645A5 JP2016532645A5 (cg-RX-API-DMAC7.html) | 2017-07-06 |
| JP6188934B2 true JP6188934B2 (ja) | 2017-08-30 |
Family
ID=52777129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520593A Active JP6188934B2 (ja) | 2013-10-07 | 2014-10-03 | デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 |
| JP2017146472A Active JP6522062B2 (ja) | 2013-10-07 | 2017-07-28 | デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017146472A Active JP6522062B2 (ja) | 2013-10-07 | 2017-07-28 | デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150098982A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3054931B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6188934B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101891186B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105764495A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2924188C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2855103T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2654702C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI629061B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015054062A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101891185B1 (ko) | 2013-10-07 | 2018-08-24 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물 |
| TWI709417B (zh) | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| RU2646512C2 (ru) | 2013-10-07 | 2018-03-05 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Устройства для трансдермальной доставки дексмедетомидина и способы их применения |
| CN105764495A (zh) * | 2013-10-07 | 2016-07-13 | 帝国制药美国公司 | 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物 |
| KR20190060007A (ko) | 2016-10-31 | 2019-05-31 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법 |
| IL267689B2 (en) | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| IL279713B2 (en) | 2018-06-27 | 2025-01-01 | Bioxcel Therapeutics Inc | Dexmedetomidine-containing layer compositions and methods for their production |
| US12472158B2 (en) | 2019-02-27 | 2025-11-18 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| KR20220002950A (ko) | 2019-05-01 | 2022-01-07 | 클렉시오 바이오사이언시스 리미티드 | 소양증의 치료 방법 |
| WO2020222192A1 (en) | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| EP3999058A4 (en) | 2019-07-19 | 2023-05-03 | Bioxcel Therapeutics, Inc. | TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN |
| WO2024037545A1 (zh) * | 2022-08-17 | 2024-02-22 | 宜昌人福药业有限责任公司 | 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
| GB2290964A (en) * | 1994-07-08 | 1996-01-17 | Arto Olavi Urtti | Transdermal drug delivery system |
| PL181582B1 (pl) * | 1995-06-07 | 2001-08-31 | Ortho Mcneil Pharm Inc | Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL |
| ES2228125T3 (es) * | 1998-10-02 | 2005-04-01 | 3M Innovative Properties Company | Sistemas de suministro de farmacos originados en las mucosas. |
| US7635488B2 (en) * | 2001-03-13 | 2009-12-22 | Dbv Technologies | Patches and uses thereof |
| KR100511492B1 (ko) * | 2002-10-11 | 2005-08-31 | 주식회사 태평양 | 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제 |
| EP1652508B1 (en) * | 2003-07-31 | 2013-12-04 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
| EP1663311A2 (en) * | 2003-09-12 | 2006-06-07 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| KR101042490B1 (ko) * | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(vr1)활성 저해제 |
| US20070134310A1 (en) * | 2005-09-23 | 2007-06-14 | Nedberge Diane E | Transdermal risperidone delivery system |
| EP2308480B1 (en) * | 2005-09-23 | 2014-08-13 | ALZA Corporation | High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications |
| JP4148988B2 (ja) * | 2006-09-11 | 2008-09-10 | 積水化学工業株式会社 | 貼付剤 |
| US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| JP5547065B2 (ja) * | 2008-05-15 | 2014-07-09 | 久光製薬株式会社 | パロノセトロンを含有する経皮吸収製剤 |
| WO2010014076A1 (en) * | 2008-07-28 | 2010-02-04 | EndogenX, Inc. | Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist |
| US9308203B2 (en) * | 2008-10-01 | 2016-04-12 | Taiwan Biotech Co., Ltd. | Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis |
| US20130072532A1 (en) * | 2010-01-08 | 2013-03-21 | Recro Pharma, Inc. | Topical transdermal dexmedetomidine compositions and methods of use thereof |
| US8563031B2 (en) * | 2010-05-27 | 2013-10-22 | Absize, Inc. | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
| CA2815898C (en) * | 2010-11-17 | 2018-12-18 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
| US20130096170A1 (en) * | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| CN105764495A (zh) * | 2013-10-07 | 2016-07-13 | 帝国制药美国公司 | 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物 |
-
2014
- 2014-10-03 CN CN201480064109.XA patent/CN105764495A/zh active Pending
- 2014-10-03 RU RU2016109631A patent/RU2654702C2/ru active
- 2014-10-03 CN CN201910851561.5A patent/CN110604728A/zh active Pending
- 2014-10-03 JP JP2016520593A patent/JP6188934B2/ja active Active
- 2014-10-03 TW TW103134523A patent/TWI629061B/zh active
- 2014-10-03 CA CA2924188A patent/CA2924188C/en active Active
- 2014-10-03 WO PCT/US2014/059057 patent/WO2015054062A2/en not_active Ceased
- 2014-10-03 KR KR1020167011598A patent/KR101891186B1/ko active Active
- 2014-10-03 KR KR1020187023714A patent/KR20180095733A/ko not_active Ceased
- 2014-10-03 US US14/505,941 patent/US20150098982A1/en not_active Abandoned
- 2014-10-03 EP EP14851606.5A patent/EP3054931B1/en active Active
- 2014-10-03 ES ES14851606T patent/ES2855103T3/es active Active
-
2017
- 2017-07-28 JP JP2017146472A patent/JP6522062B2/ja active Active
-
2024
- 2024-03-29 US US18/621,397 patent/US20240245652A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240245652A1 (en) | 2024-07-25 |
| BR112016007327A2 (pt) | 2017-08-01 |
| US20150098982A1 (en) | 2015-04-09 |
| CA2924188C (en) | 2018-12-18 |
| EP3054931A2 (en) | 2016-08-17 |
| CA2924188A1 (en) | 2015-04-16 |
| TW201524506A (zh) | 2015-07-01 |
| WO2015054062A2 (en) | 2015-04-16 |
| JP2018008984A (ja) | 2018-01-18 |
| KR101891186B1 (ko) | 2018-08-24 |
| KR20180095733A (ko) | 2018-08-27 |
| TWI629061B (zh) | 2018-07-11 |
| RU2016109631A (ru) | 2017-11-15 |
| RU2654702C2 (ru) | 2018-05-22 |
| CN110604728A (zh) | 2019-12-24 |
| ES2855103T3 (es) | 2021-09-23 |
| KR20160062159A (ko) | 2016-06-01 |
| EP3054931A4 (en) | 2017-04-05 |
| EP3054931B1 (en) | 2020-12-23 |
| JP2016532645A (ja) | 2016-10-20 |
| CN105764495A (zh) | 2016-07-13 |
| JP6522062B2 (ja) | 2019-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6494818B2 (ja) | デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物 | |
| US20240245652A1 (en) | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions | |
| US10772871B2 (en) | Dexmedetomidine transdermal delivery devices and methods for using the same | |
| JP6188933B2 (ja) | 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物 | |
| EP2938391A1 (en) | Extended buprenorphine transdermal delivery compositions and methods for using the same | |
| JP6208859B6 (ja) | デクスメデトミジン経皮送達デバイス及びその使用法 | |
| HK40018815A (en) | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions | |
| HK40018790A (en) | Dexmedetomidine transdermal delivery devices and methods for using the same | |
| BR112016007327B1 (pt) | Uso de dispositivo de distribuição transdérmica para controlar dor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160601 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160601 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170224 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170524 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170703 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170801 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6188934 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |